Yazar "Deveci, Ozcan" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    A case of acute hemorrhagic cystitis caused by salmonella paratyphi a in a pediatric patient
    (2012) Yula, Erkan; Deveci, Ozcan; Toka-Ozer, Turkan; Tekin, Alicem; Inci, Melek; Karakus, Ali
    It is a very rare medical condition that Urinary tract infection (UTI) caused by Salmonella species. Seven-year-old boy admitted to our hospital with complaint of lower abdominal pain, burning and pain during urination (dysuria), nausea and increased fever. The patient had normal vital signs but abdominal examination revealed bilateral suprapubic tenderness. In the laboratory, it was found the amount of hemoglobin 12.9 g/dL, red blood cell count 4.8 million/mm3, white blood cell count 11.800/mm3, platelet count 275.000/mm3, level of C-reactive protein 30.2 mg/L, serologically S. paratyphi A "O" antibody (1/160) and S. paratyphi A "H" antibody (1/320) positivity. Urine examination showed gross hematuria and leukocyte esterase was positive. Urine culture was performed and isolate obtained urine culture was identified with conventional methods. Result of urine culture was reported as Salmonella species and isolate was determined as Salmonella paratyphi A by using anti-sera during the advanced identification. Results of radiological imaging were found normal. The patient was diagnosed as acute hemorrhagic cystitis caused by S. paratyphi A and received ceftriaxone treatment for seven days and had a full recovery. We conclude that in case of acute hemorrhagic cystitis, S. paratyphi A should be considered as causative agent in endemic areas.
  • [ N/A ]
    Öğe
    Prognostic significance of transforming growth factor-beta-1 in chronic hepatitis C virus infection
    (Academic Journals, 2012) Deveci, Ozcan; Agalar, Canan; Demirdal, Tuna; Demirturk, Nese; Yula, Erkan; Tekin, Alicem; Kaygusuz, Sedat
    Interferon treatment in hepatitis C virus (HCV) infection is expensive and has various adverse effects. Some markers may help in making decision to stop or maintain the treatment. The aim of this study was to evaluate the effectiveness of serum transforming growth factor beta-1 (TGF-beta 1) in assessing outcome of interferon treatment in patients with HCV infection. Twelve patients with chronic HCV infections included in the study as treatment group [Treatment group: anti-HCV (+), HCV RNA (+)] and 12 patients with anti-HCV positive, HCV-RNA negative and normal liver function tests included as control group. All patients in the treatment group were administered with peginterferon and ribavirin for 24 weeks. HCV-RNA levels were determined by realtime-PCR and TGF-beta 1 levels were measured with ELISA methods, at the beginning and 24th week of the treatment. Mann-Whitney U Test and Wilcoxon Test were used to compare variables within and between groups. Median age and male/female ratios were 46 years and 5/7, and 45 years and 3/9 for treatment groups and control group, respectively. Although no difference was found in TGF-beta 1 levels at the beginning of the treatment between groups (p>0.05), significantly decreased TGF-beta 1 levels were observed following 24 weeks of interferon treatment in treatment group (p=0.015). Despite limited number of patients, our data suggested that, TGF-beta 1 levels may be used as a prognostic marker for effectiveness of interferon treatment in patients with hepatitis C virus infection.